inclacumab

Home
Ligands
inclacumab

GtoPdb Ligand ID: 12312

Synonyms: HuMab 002 [2] | LC1004-002 | RO-4905417 | RO4905417

Comment: Inclacumab (formerly RO4905417) is an IgG4κ monoclonal antobody that targets selectin P (CD62; SELP) [2] that was initially designed for potential to promote anti-inflammatory and antithrombotic effects as a mechanism to reduce atherosclerosis. It blocks the interaction between selectin P and its primary ligand, P-selectin glycoprotein ligand-1 (PSGL-1). Inclacumab was later repositioned to reduce vaso-occlusive crises in patients with sickle cell disease.

References
1. FDA. Inclacumab. Accessed on 07/08/2023. Modified on 07/08/2023. fda.gov, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=875522
2. Graus Y, Himber J, Jansen-Molenaar M, Kling D, Kopetzky E, Parren P, Reber F, Steiner B, Stern A, Strein P et al.. (2005) Anti-p-selectin antibodies. Patent number: WO2005100402A1. Assignee: F.Hoffmann-La Roche Ag. Priority date: 05/04/2005. Publication date: 27/10/2005.

References

1. FDA.
Inclacumab.
Accessed on 07/08/2023. Modified on 07/08/2023. fda.gov, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=875522

2. Graus Y, Himber J, Jansen-Molenaar M, Kling D, Kopetzky E, Parren P, Reber F, Steiner B, Stern A, Strein P et al.. (2005)
Anti-p-selectin antibodies.
Patent number: WO2005100402A1. Assignee: F.Hoffmann-La Roche Ag. Priority date: 05/04/2005. Publication date: 27/10/2005.